ResApp Health Limited (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResApp Health Limited (ASX: RAP)
    Latest News

    Green stock market graph with a rising arrow symbolising a rising share price.
    Share Gainers

    Why Beach, BHP, New Hope, and ResApp shares are charging higher

    These ASX shares are having strong days...

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Share Gainers

    Here's why the ResApp (ASX:RAP) share price is skyrocketing 60% today

    More than 2 years after the WHO declared a pandemic, COVID-19 remains a prevalent virus.

    Read more »

    Hands grabbing for high rung on a ladder pointing to the sky
    Healthcare Shares

    Resapp share (ASX:RAP) price climbs 5% on Chinese patent news

    Investors are piling into Resapp on huge volume today.

    Read more »

    A businessman leaps in the air outside a city building in the CBD.
    Healthcare Shares

    ResApp (ASX:RAP) share price jumps 5% on regulatory approval

    What did ResApp announce?

    Read more »

    Jumbo Interactive staffers shaking hands around table agreeing to an acquisition
    Healthcare Shares

    ResApp (ASX:RAP) share price rockets 11% on new Johnson & Johnson deal

    It's been a good day for the digital health company's shares...

    Read more »

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Market News

    ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

    The company's shares are continuing on yesterday's gains...

    Read more »

    doctor and nurse smiling in a hospital ward representing rising share price
    52-Week Highs

    ResApp (ASX:RAP) share price races 18% higher today, up 65% in a week

    It's been a great week for ResApp shareholders...

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    Why the ResApp (ASX:RAP) share price is flying 25% higher today

    Respiratory illnesses have come under increasing scrutiny during the pandemic.

    Read more »

    ehealth
    Healthcare Shares

    ResApp (ASX:RAP) share price surges 5% on new agreement

    The ResApp Health Ltd (ASX: RAP) share price is 5% higher today following a new agreement. We take a closer…

    Read more »

    Thumbs down Facebook icon over dark screen
    Capital Raising

    Why the ResApp (ASX:RAP) share price is down 9% today

    The ResApp Health Ltd (ASX:RAP) share price is sinking on Monday after announcing the completion of a $5.5 million capital…

    Read more »

    white arrow pointing down
    Share Fallers

    Why Corp Travel Management, IGO, Limeade, & ResApp are tumbling lower

    Corporate Travel Management Ltd (ASX:CTD) and ResApp Health Ltd (ASX:RAP) are two of four ASX shares tumbling lower on Wednesday...

    Read more »

    Share Market News

    ASX stock of the day: Why ResApp Heath (ASX:RAP) shares are soaring

    The ResApp Health Ltd (ASX: RAP) share price is soaring today, up more than 9.7%. Here's why this ASX share…

    Read more »

    RAP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
    Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
    Dr Michael Stein Non-Executive Director Apr 2020
    Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
    Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
    Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
    Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
    Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
    Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
    Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
    Ms Nicola (Nicki) Maxine Farley Company Secretary
    -
    Nicola (Nicki) Maxine Farley Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 90,509,172 10.53%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> 46,498,352 5.41%
    J P Morgan Nominees Australia Pty Limited 22,398,291 2.61%
    Mr Frank Weng Thong Chew 18,453,000 2.15%
    HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> 17,974,966 2.09%
    BNP Paribas Noms Pty Ltd <DRP> 14,977,050 1.74%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 12,567,531 1.46%
    Mr Yongsheng Peng & Mrs Yuezhen Xie 11,667,602 1.36%
    Mr Anthony James Keating 10,225,000 1.19%
    Citicorp Nominees Pty Limited 9,962,873 1.16%
    Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> 8,437,500 0.98%
    Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
    CEM International (Asia) Pty Ltd 7,849,888 0.91%
    Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> 7,510,228 0.87%
    Mr Trent Antony Goodrick 7,000,000 0.81%
    Queensland Forest Industries Pty Ltd 6,502,500 0.76%
    Mishtalem Pty Ltd 6,500,000 0.76%
    Super Dino Pty Ltd <Dino Super A/C> 5,430,779 0.63%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,378,484 0.63%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.61%

    Profile

    since

    Note